^
Association details:
| Biomarker: | RB1 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Ibrance (palbociclib) (CDK4/6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting cell cycle and hormone receptor pathways in cancer
Excerpt:
This study shows that selective CDK4/6 inhibition, using PD either as a single-agent or in combination, hinders key proliferative pathways necessary for disease progression and that RB status is a critical prognostic determinant for therapeutic efficacy.
DOI:
10.1038/onc.2013.83